anti-spike antibody – Page 9 – Communicable Diseases Research

Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro

보존된 N-글리코실화를 표적으로 하는 것은 시험관 내에서 SARS-CoV-2 변이체 감염을 차단합니다

Article

Published on 2021-12-012022-09-11
Journal: EBioMedicine [Category] SARS, 변종, 진단,

Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine

이식 전에 예방 접종을 받은 신장 이식 환자는 SARS-CoV-2 백신에 대해 우수한 체액 반응을 유지합니다.

Article

Published on 2021-12-012022-09-12
Journal: Clinical transplantation [Category] SARS, 진단,

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents

MVA 벡터 백신의 비강 내 전달은 설치류의 SARS-CoV-2에 대한 효과적인 폐 면역을 유도합니다

Immunology

Published on 2021-11-112022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단,

[키워드] Against anti-spike antibodies anti-spike antibody Antigen applied approach Booster vaccine bronchus-associated lymphoid tissue (BALT) CD4 CD8 component delivery effective followed by hamster hamsters identify IgA IgA antibodies IgA antibody immune responses Immunity immunization induce intramuscular intranasal Local lung Lung infection Lungs memory T memory T cell memory T cells mice modified vaccinia virus Ankara (MVA) Neutralizing Neutralizing antibodies pathology priming PROTECT protocol protocols pulmonary respiratory respiratory tract rodent SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 variant SARS-CoV-2-S serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein systemic immune response systemic immune responses T cell T cells tested Th1 Th2 titers of IgG treatment regimen vaccination Vaccine vaccine candidate vaccinia vector Viral viral infections virus Virus neutralization
[DOI] 10.3389/fimmu.2021.772240 PMC 바로가기 [Article Type] Immunology

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

Original Article

Published on 2021-10-012022-10-31
Journal: Clinical microbiology and infection : the official [Category] COVID-19, MERS, SARS,

[키워드] Abbott SARS-CoV-2 IgG acute respiratory syndrome Anti-spike anti-spike antibody anti-spike antibody response anti-spike IgG response antibody Antibody Response Antibody testing coronavirus detectable determinant dose dosing interval Efficacy Evidence first dose first vaccination HCW HCWs healthcare worker identify Infection investigated median multivariable logistic regression objective Pfizer Pfizer–BioNTech predictor Quantitative anti-spike antibody receiving recipient recipients response Result SARS-CoV-2 SARS-CoV-2 PCR SARS-CoV-2 vaccination second vaccination Serological testing serology seropositive Sex tested vaccination Vaccine vaccine dose Vaccines were measured
[DOI] 10.1016/j.cmi.2021.05.041 PMC 바로가기 [Article Type] Original Article

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers

코로나19에서 치유된 오크렐리주맙 치료를 받은 다발성 경화증 환자의 SARS-CoV-2에 대한 T-세포 반응

Article

Published on 2021-10-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] MERS, 진단, 치료법,

[키워드] abrogate absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-S anti-SARS-CoV-2 antibody anti-spike antibody antibodies approach B-cell CD20 CD4/CD8 Concentration Coronavirus-2 COVID-19 depleting detect detectable diagnostic Disease modifying therapies domain enrolled FIVE glycoprotein IGRA immune response immunodominant Immunological response impair IMPROVE interferon Interferon-gamma multiple sclerosis natural infection not affect Nucleocapsid phosphoprotein Ocrelizumab Patient patients patients treated peptide peptides Peripheral blood receiving reduce reduction respiratory SARS-CoV-2 SARS-COV-2 infection sequence Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Specific T-cell response spike glycoprotein Stimulation subset T-cell Response T-cell responses T-lymphocyte T-lymphocyte, peptides. the Spike therapy Treatment vaccination Whole blood
[DOI] 10.1016/j.msard.2021.103157 PMC 바로가기 [Article Type] Article

SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays

의료 종사자의 SARS-CoV-2 항체 검사: 상업적으로 이용 가능한 3가지 항체 분석의 임상 성능 비교

Comparative Study

Published on 2021-09-292022-09-10
Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, 치료기술, 치료법,

[키워드] 95% CI 95% confidence interval Abbott Abbott Architect SARS-CoV-2 IgG acute respiratory syndrome acute respiratory syndrome coronavirus anti-SARS-CoV-2 anti-spike antibody antibody antibody assays SARS-CoV-2 Asian assays blood sample Blood samples Care choice clinical coronavirus correlated COVID-19 infection COVID-19 pandemic COVID-19 serological assays demonstrated detected antibody Diagnosis distance Elecsys ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay Ethnicity Factor functional HCW Health Health care help IgG Immunity Immunoglobulin Immunoglobulin G indicate Infection infections male natural infection Odds ratio PCR PCR-confirmed PCR-confirmed COVID-19 performance positive public health respiratory retained Roche Roche Elecsys SARS-CoV-2 panantibody sample selection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 serological assay SARS-CoV-2 seroprevalence sensitivity Serological assay serological response Seronegativity Seroprevalence serum sample serum samples severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe symptoms Sex significant difference significant differences significantly similar studies study period subset symptom severity tested Testing the timing
[DOI] 10.1128/Spectrum.00391-21 PMC 바로가기 [Article Type] Comparative Study

Sensitive detection of anti-spike antibodies enables improved understanding of SARS-CoV-2 pathogenesis

스파이크 방지 항체의 민감한 검출을 통해 SARS-CoV-2 병인에 대한 이해 향상

Editorial

Published on 2021-09-012022-09-11
Journal: Immunology [Category] SARS, 진단, 치료기술,

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

SARS-CoV-2 mRNA 백신(BNT162b2) 2회 접종 후 의료 전문가의 조기 항체 반응

Multicenter Study

Published on 2021-09-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, 진단, 치료법,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody titre antibody titres baseline Belgium blood sample Blood samples BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine clinical trial collected conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine disease dose dose regimen hcp health-care Humoral response immune response individual individuals infected individual infected individuals lead mRNA vaccine multicentre nucleocapsid of BNT162b2 optimum dose professional reached Receptor binding domain respiratory S1 subunit SARS-CoV-2 SARS-CoV-2 nucleocapsid second dose seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly higher single dose Spike protein Support the S1 subunit the SARS-CoV-2 the spike protein titre two-dose regimen uninfected Vaccine Volunteer were excluded were measured
[DOI] 10.1016/j.cmi.2021.05.004 PMC 바로가기 [Article Type] Multicenter Study

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

회복기 및 BNT162b2 백신 접종 혈청에 의한 SARS-CoV-2 변이체의 중화

Article

Published on 2021-08-262022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] (alpha (Beta age Alpha anti-spike antibodies anti-spike antibody Antibody titers B.1.1.7 B.1.351 BNT162b2 BNT162b2 vaccine Cohort convalescent convalescent COVID-19 patient convalescent COVID-19 patients convalescent serum COVID-19 patients Effective vaccines escape evaluate human sera increased risk infect lead less neutralization neutralized neutralizing activities Neutralizing antibody titer neutralizing antibody titers of BNT162b2 Patient patient age Re-infection recipient reduced RNA vaccines SARS- CoV-2 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants serum serum antibodies vaccinated individuals Vaccine variant variants
[DOI] 10.1038/s41467-021-25479-6 PMC 바로가기 [Article Type] Article

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Article

Published on 2021-08-062022-10-29
Journal: Nature Communications [Category] COVID-19, MERS, SARS,

[키워드] 229E absence anti-spike antibody antibodies antibody Antibody neutralization Asymptomatic characterisation Characteristics Cohort common cold COVID-19 COVID-19 disease cross-reactive effective endemic human coronaviruses Evidence flow cytometry Health care worker healthcare worker HKU1 human coronavirus IgA IgG IgG level IgM immune response Immunity increase individual Infection kinetics of antibody Level neutralisation activity neutralizing capacity NL63 nucleocapsid antigen OC43 post-symptom onset protective effect protective immunity protective role quantified SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antigen SARS-COV-2 infection seropositive individuals Seroprevalence Seven significantly higher Surveillance symptomatic viral infection
[DOI] 10.1038/s41467-021-24979-9 PMC 바로가기 [Article Type] Article